D Chisholm1, M Heslin2, S Docrat3, S Nanda4, R Shidhaye4, N Upadhaya5, M Jordans5, J Abdulmalik6, S Olayiwola6, O Gureje6, D Kizza7, J Mugisha7, F Kigozi7, C Hanlon2, M Adugna8, R Sanders9, C Pretorius9, G Thornicroft2, C Lund2. 1. Department of Mental Health and Substance Abuse,World Health Organization,Geneva,Switzerland. 2. Institute of Psychiatry,Psychology and Neuroscience,King's College London,London,UK. 3. Department of Psychiatry and Mental Health,Alan J Flisher Centre for Public Mental Health,University of Cape Town,Cape Town,South Africa. 4. Public Health Foundation of India,India. 5. Transcultural Psychosocial Organization (TPO),Nepal. 6. Department of Psychiatry,University of Ibadan,Nigeria. 7. Butabika National Referral and Teaching,Mental Hospital,Uganda. 8. Federal Ministry of Health,Ethiopia. 9. Avenir Health,Glastonbury,Connecticut,USA.
Abstract
BACKGROUND: Although financing represents a critical component of health system strengthening and also a defining concern of efforts to move towards universal health coverage, many countries lack the tools and capacity to plan effectively for service scale-up. As part of a multi-country collaborative study (the Emerald project), we set out to develop, test and apply a fully integrated health systems resource planning and health impact tool for mental, neurological and substance use (MNS) disorders. METHODS: A new module of the existing UN strategic planning OneHealth Tool was developed, which identifies health system resources required to scale-up a range of specified interventions for MNS disorders and also projects expected health gains at the population level. We conducted local capacity-building in its use, as well as stakeholder consultations, then tested and calibrated all model parameters, and applied the tool to three priority mental and neurological disorders (psychosis, depression and epilepsy) in six low- and middle-income countries. RESULTS: Resource needs for scaling-up mental health services to reach desired coverage goals are substantial compared with the current allocation of resources in the six represented countries but are not large in absolute terms. In four of the Emerald study countries (Ethiopia, India, Nepal and Uganda), the cost of delivering key interventions for psychosis, depression and epilepsy at existing treatment coverage is estimated at US$ 0.06-0.33 per capita of total population per year (in Nigeria and South Africa it is US$ 1.36-1.92). By comparison, the projected cost per capita at target levels of coverage approaches US$ 5 per capita in Nigeria and South Africa, and ranges from US$ 0.14-1.27 in the other four countries. Implementation of such a package of care at target levels of coverage is expected to yield between 291 and 947 healthy life years per one million populations, which represents a substantial health gain for the currently neglected and underserved sub-populations suffering from psychosis, depression and epilepsy. CONCLUSIONS: This newly developed and validated module of OneHealth tool can be used, especially within the context of integrated health planning at the national level, to generate contextualised estimates of the resource needs, costs and health impacts of scaled-up mental health service delivery.
BACKGROUND: Although financing represents a critical component of health system strengthening and also a defining concern of efforts to move towards universal health coverage, many countries lack the tools and capacity to plan effectively for service scale-up. As part of a multi-country collaborative study (the Emerald project), we set out to develop, test and apply a fully integrated health systems resource planning and health impact tool for mental, neurological and substance use (MNS) disorders. METHODS: A new module of the existing UN strategic planning OneHealth Tool was developed, which identifies health system resources required to scale-up a range of specified interventions for MNS disorders and also projects expected health gains at the population level. We conducted local capacity-building in its use, as well as stakeholder consultations, then tested and calibrated all model parameters, and applied the tool to three priority mental and neurological disorders (psychosis, depression and epilepsy) in six low- and middle-income countries. RESULTS: Resource needs for scaling-up mental health services to reach desired coverage goals are substantial compared with the current allocation of resources in the six represented countries but are not large in absolute terms. In four of the Emerald study countries (Ethiopia, India, Nepal and Uganda), the cost of delivering key interventions for psychosis, depression and epilepsy at existing treatment coverage is estimated at US$ 0.06-0.33 per capita of total population per year (in Nigeria and South Africa it is US$ 1.36-1.92). By comparison, the projected cost per capita at target levels of coverage approaches US$ 5 per capita in Nigeria and South Africa, and ranges from US$ 0.14-1.27 in the other four countries. Implementation of such a package of care at target levels of coverage is expected to yield between 291 and 947 healthy life years per one million populations, which represents a substantial health gain for the currently neglected and underserved sub-populations suffering from psychosis, depression and epilepsy. CONCLUSIONS: This newly developed and validated module of OneHealth tool can be used, especially within the context of integrated health planning at the national level, to generate contextualised estimates of the resource needs, costs and health impacts of scaled-up mental health service delivery.
Entities:
Keywords:
Economic issues; epidemiology; health service research; mental health
Authors: Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos Journal: Lancet Date: 2013-08-29 Impact factor: 79.321
Authors: Joshua A Salomon; Theo Vos; Daniel R Hogan; Michael Gagnon; Mohsen Naghavi; Ali Mokdad; Nazma Begum; Razibuzzaman Shah; Muhammad Karyana; Soewarta Kosen; Mario Reyna Farje; Gilberto Moncada; Arup Dutta; Sunil Sazawal; Andrew Dyer; Jason Seiler; Victor Aboyans; Lesley Baker; Amanda Baxter; Emelia J Benjamin; Kavi Bhalla; Aref Bin Abdulhak; Fiona Blyth; Rupert Bourne; Tasanee Braithwaite; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Rachelle Buchbinder; Peter Burney; Bianca Calabria; Honglei Chen; Sumeet S Chugh; Rebecca Cooley; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Adrian Davis; Louisa Degenhardt; Cesar Díaz-Torné; E Ray Dorsey; Tim Driscoll; Karen Edmond; Alexis Elbaz; Majid Ezzati; Valery Feigin; Cleusa P Ferri; Abraham D Flaxman; Louise Flood; Marlene Fransen; Kana Fuse; Belinda J Gabbe; Richard F Gillum; Juanita Haagsma; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Abdullah Hel-Baqui; Hans W Hoek; Howard Hoffman; Emily Hogeland; Damian Hoy; Deborah Jarvis; Ganesan Karthikeyan; Lisa Marie Knowlton; Tim Lathlean; Janet L Leasher; Stephen S Lim; Steven E Lipshultz; Alan D Lopez; Rafael Lozano; Ronan Lyons; Reza Malekzadeh; Wagner Marcenes; Lyn March; David J Margolis; Neil McGill; John McGrath; George A Mensah; Ana-Claire Meyer; Catherine Michaud; Andrew Moran; Rintaro Mori; Michele E Murdoch; Luigi Naldi; Charles R Newton; Rosana Norman; Saad B Omer; Richard Osborne; Neil Pearce; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Farshad Pourmalek; Martin Prince; Jürgen T Rehm; Guiseppe Remuzzi; Kathryn Richardson; Robin Room; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Maria Segui-Gomez; Saeid Shahraz; Kenji Shibuya; David Singh; Karen Sliwa; Emma Smith; Isabelle Soerjomataram; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Hugh R Taylor; Imad M Tleyjeh; Marieke J van der Werf; Wendy L Watson; David J Weatherall; Robert Weintraub; Marc G Weisskopf; Harvey Whiteford; James D Wilkinson; Anthony D Woolf; Zhi-Jie Zheng; Christopher J L Murray; Jost B Jonas Journal: Lancet Date: 2012-12-15 Impact factor: 79.321
Authors: Maya Semrau; Sara Evans-Lacko; Atalay Alem; Jose Luis Ayuso-Mateos; Dan Chisholm; Oye Gureje; Charlotte Hanlon; Mark Jordans; Fred Kigozi; Heidi Lempp; Crick Lund; Inge Petersen; Rahul Shidhaye; Graham Thornicroft Journal: BMC Med Date: 2015-04-10 Impact factor: 8.775
Authors: M Semrau; A Alem; J Abdulmalik; S Docrat; S Evans-Lacko; O Gureje; F Kigozi; H Lempp; C Lund; I Petersen; R Shidhaye; G Thornicroft; C Hanlon Journal: Epidemiol Psychiatr Sci Date: 2017-10-02 Impact factor: 6.892
Authors: Caroline Kuo; Ashleigh LoVette; Dan J Stein; Lucie D Cluver; Larry K Brown; Millicent Atujuna; Tracy R G Gladstone; Jacqueline Martin; William Beardslee Journal: Transcult Psychiatry Date: 2018-10-05
Authors: Catherine Barker Cantelmo; Momoe Takeuchi; Karin Stenberg; Lo Veasnakiry; Ros Chhun Eang; Mo Mai; Eijiro Murakoshi Journal: Bull World Health Organ Date: 2018-06-04 Impact factor: 9.408